Literature DB >> 27247135

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.

Darryl P Leong1, François Caron2, Christopher Hillis3, Annie Duan2, Jeff S Healey1, Graeme Fraser3, Deborah Siegal4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27247135     DOI： 10.1182/blood-2016-05-712828

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  68 in total

Review 1.  Bruton Tyrosine Kinase Inhibitors: Present and Future.

Authors:  Jan A Burger
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

Review 3.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

Review 4.  Electrophysiologic Complications in Cancer Patients.

Authors:  Dae Hyun Lee; Sanjay Chandrashekhar; Michael G Fradley
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

5.  Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.

Authors:  John C Byrd; William G Wierda; Anna Schuh; Stephen Devereux; Jorge M Chaves; Jennifer R Brown; Peter Hillmen; Peter Martin; Farrukh T Awan; Deborah M Stephens; Paolo Ghia; Jacqueline Barrientos; John M Pagel; Jennifer A Woyach; Kathleen Burke; Todd Covey; Michael Gulrajani; Ahmed Hamdy; Raquel Izumi; Melanie M Frigault; Priti Patel; Wayne Rothbaum; Min Hui Wang; Susan O'Brien; Richard R Furman
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

Review 6.  Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week.

Authors:  Ramya C Mosarla; Muthiah Vaduganathan; Arman Qamar; Javid Moslehi; Gregory Piazza; Robert P Giugliano
Journal:  J Am Coll Cardiol       Date:  2019-03-26       Impact factor: 24.094

7.  Ventricular arrhythmias and sudden death in patients taking ibrutinib.

Authors:  Benjamin L Lampson; Lijian Yu; Robert J Glynn; Jacqueline C Barrientos; Eric D Jacobsen; Versha Banerji; Jeffrey A Jones; Renata Walewska; Kerry J Savage; Gregory F Michaud; Javid J Moslehi; Jennifer R Brown
Journal:  Blood       Date:  2017-02-21       Impact factor: 22.113

Review 8.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

Review 9.  Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies.

Authors:  Isaac B Rhea; Alexander R Lyon; Michael G Fradley
Journal:  Curr Oncol Rep       Date:  2019-04-04       Impact factor: 5.075

Review 10.  Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach.

Authors:  Paolo Strati; Alessandra Ferrajoli
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.